Vibha Sharma
Her fields of interest include the EU Pharmacovigilance legislation and the EU Paediatrics Regulation on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.
Before joining Informa, she was principal correspondent with India's national newspaper Hindustan Times, where she reported on health and medical issues, besides several other topics. She has also worked with two other Indian national dailies, The Indian Express and The Asian Age.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Vibha Sharma
Patient Voice Makes Impact In Scientific Advice From EU HTA Network
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Global Pharma Guidance Tracker – November 2019
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Global Medtech Guidance Tracker: November 2019
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-eight guidance documents have been posted on the tracker since its last update.
Differences Put Aside As ICH Finalizes Guide On Post Approval Changes
An international guideline on managing post approval changes to drugs, which was initially criticized because of its incompatibility with legal frameworks in certain ICH regions such as the EU, has been finalized.
EU Produces More Guidance For Upcoming Clinical Trials Regulation
The European Commission has issued a new template on trial recruitment and informed consent procedures and has updated its guidance on the provisions of the EU Clinical Trials Regulation that allow a trial to be conditionally authorized.
Irish Regulator Invites Feedback On Strategic Plan For 2021-2025
Ireland’s drug and medical device regulator is seeking stakeholder views on what its priorities should be over the next five years, given the uncertainties of Brexit and impending regulatory changes.